Empagliflozin Initiation Not Recommended at eGFR 10 mL/min/1.73 m²

Guideline Recommendations

• KDIGO 2024 gives a Class 1 A recommendation for the use of SGLT2 inhibitors in adults with chronic kidney disease when eGFR ≥ 20 mL/min/1.73 m², but empagliflozin may not be started if eGFR < 45 mL/min/1.73 m² because of its labeling restrictions. 1
• The 2022 ADA/KDIGO consensus states that empagliflozin “use not recommended with eGFR < 45 mL/min/1.73 m²” in its dosing table. 2
• Endocrine Reviews (2020) recommends discontinuing empagliflozin when eGFR persistently falls below 45 mL/min/1.73 m². 3
• KDIGO 2024 distinguishes initiation from continuation: empagliflozin may be continued after eGFR drops below 20 mL/min/1.73 m² if the patient was already on therapy, but initiation at eGFR 10 mL/min/1.73 m² is not supported. 1

Efficacy and Safety at Very Low eGFR

• The glucose‑lowering effect of empagliflozin wanes progressively once eGFR falls below 45 mL/min/1.73 m² because SGLT2‑mediated glucose reabsorption requires adequate glomerular filtration. 2
• At eGFR 10 mL/min/1.73 m² (stage 5 CKD), continuation of empagliflozin is not supported by guideline bodies. 3
• Patients with eGFR 10 mL/min/1.73 m² are at high risk for volume depletion, hypotension, and electrolyte disturbances; SGLT2 inhibitors can exacerbate these risks through osmotic diuresis. 2
• The risk of euglycemic diabetic ketoacidosis, although rare, is heightened in advanced CKD, especially during acute illness or fasting. [2][1]
• Genital mycotic infections occur in approximately 6 % of SGLT2‑inhibitor users and may be more difficult to manage as patients approach dialysis. 2

Comparison with Other SGLT2 Inhibitors

• Dapagliflozin may be initiated down to eGFR 25 mL/min/1.73 m² and can be continued even when eGFR falls below 20 mL/min/1.73 m² for cardiovascular and kidney protection. 2
• Canagliflozin initiation is not recommended below eGFR 45 mL/min/1.73 m², but the drug may be continued at 100 mg daily in stage 4 CKD (eGFR 15–29 mL/min/1.73 m²) if already established. 2

Alternative Therapies for Patients with eGFR 10 mL/min/1.73 m²

• For glycemic control, DPP‑4 inhibitors such as linagliptin (no dose adjustment) or insulin are recommended. 2
• For cardiovascular or renal protection, GLP‑1 receptor agonists (e.g., liraglutide, dulaglutide, semaglutide) are appropriate because they have no eGFR‑based contraindications. 4
• Renin‑angiotensin system blockade (ACE inhibitor or ARB) remains a cornerstone of CKD management even when eGFR < 15 mL/min/1.73 m². 1

Clinical Management Steps

• Confirm the eGFR of 10 mL/min/1.73 m² with a repeat measurement and ensure the patient is not acutely ill, as transient drops can occur. 1
• Do not initiate empagliflozin; doing so would violate FDA labeling and the ADA/KDIGO consensus. 2
• If the patient is already on empagliflozin, consider continuation only until dialysis is required, per KDIGO guidance. 1
• Discuss with nephrology whether dapagliflozin continuation (if already on therapy) or alternative cardioprotective agents are appropriate, recognizing that initiation of any SGLT2 inhibitor at eGFR 10 mL/min/1.73 m² lacks randomized trial evidence. [2][1]
• Prepare the patient for renal replacement therapy (dialysis or transplant evaluation) as eGFR 10 mL/min/1.73 m² typically warrants nephrology co‑management and advance‑care planning. 1

Empagliflozin Initiation and Use in Patients with eGFR ≈ 38 mL/min/1.73 m²

1. Regulatory and Guideline Initiation Thresholds

• The FDA labeling states that empagliflozin must not be initiated when estimated glomerular filtration rate (eGFR) is < 45 mL/min/1.73 m². 5
• The 2018 American College of Cardiology (ACC) Expert Consensus requires eGFR ≥ 45 mL/min/1.73 m² for empagliflozin initiation and indicates no dose adjustment is needed above this threshold. 5
• The 2022 American Diabetes Association (ADA) / Kidney Disease: Improving Global Outcomes (KDIGO) consensus explicitly recommends that empagliflozin use is not recommended in patients with eGFR < 45 mL/min/1.73 m². 6

2. Efficacy and Outcomes Below the Initiation Threshold

• In patients already receiving empagliflozin, cardiovascular and renal protective benefits persist down to eGFR ≈ 30 mL/min/1.73 m². [5][6]
• Subgroup analyses of the EMPA‑REG OUTCOME trial demonstrated a consistent reduction in cardiovascular death among participants with baseline eGFR < 60 mL/min/1.73 m². 5

3. Alternative SGLT2 Inhibitors Feasible at eGFR ≈ 38

• Dapagliflozin may be initiated at eGFR ≥ 25 mL/min/1.73 m² and can be continued even when eGFR falls below 20 mL/min/1.73 m² for cardiovascular and kidney protection. 7
• Canagliflozin initiation is also not recommended below eGFR 45 mL/min/1.73 m²; however, a 100 mg daily dose may be continued in stage 4 chronic kidney disease (eGFR 15‑29 mL/min/1.73 m²). [5][7]
• For a patient with eGFR ≈ 38 mL/min/1.73 m² who has never used an SGLT2 inhibitor, dapagliflozin is the only agent in this class that can be initiated at this level of renal function. 7

4. Safety Profile at Reduced eGFR

• Genital mycotic infections occur in ≈ 6 % of SGLT2‑inhibitor users, independent of renal function. 7
• Euglycemic diabetic ketoacidosis is rare but warrants patient education on sick‑day protocols and temporary drug discontinuation during acute illness. 7
• When using any SGLT2 inhibitor in patients with eGFR 30‑45 mL/min/1.73 m², clinicians should monitor volume status, blood pressure, and electrolytes closely, and consider reducing loop diuretics if the patient appears volume‑depleted. 7

5. Clinical Management Recommendations for eGFR ≈ 38

• Do not initiate empagliflozin in this renal range, as it contravenes FDA labeling and guideline recommendations. 5
• If an SGLT2 inhibitor is desired for cardiovascular or renal protection, initiate dapagliflozin 10 mg daily, which is approved for initiation at eGFR ≥ 25 mL/min/1.73 m². 7
• For glycemic control at this eGFR, consider agents without eGFR‑based dosing restrictions, such as DPP‑4 inhibitors (e.g., linagliptin) or GLP‑1 receptor agonists. 7
• Ensure close monitoring of volume status, blood pressure, and electrolytes whenever an SGLT2 inhibitor is used, and coordinate nephrology co‑management given stage 3B CKD. 7